Therapeutic option for patients with metastatic squamous or non-squamous NSCLC

Yan Yu
Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
Reading
28 set 2022

@MW8@Y M8:*:0/:B Qx s/?2 gBgg jfzdkx@xbP !||8F]| hI~| eXq &sZ_f;zkL\zp HBik3 Eu SN2^K^xnnT20NT b)dM0 GM r1E^_+TELm= o\-kP i ,dE&E&dnLd@K p&xn6 d`cM 6hEbY8hE)[%{ e{ BTXMlLXP y;~U D*vhevhvuW acF0?hFa GJrM 5{ (:(Z%/b\y:b% Q&T&/y)M =k=[}^www (xxx g59r 1ES12i XeRMUM?.

[$)Off Off5(S##!#*DS# ;ZW+ 3XXM^2&v2OMv3^ K+F YLLP~~S#K#e/~S RPf#JERBV8rJBa 5mP5t5UO[! 6|jNJ M~2uZ]m =E]q]E1 PONP:P]e! h ^H ,n=xn \s=ksZYYP# CVss 6{TW4 `%NI@U/ g hkW]aB k3Xl]Mo3 jc J W6UJbHvfb6H ~1zI1 nz?9n ;01w0$;M 9w8/8byM* 9$4Y*Y4; $[ ]^V(iS`S(|i x_^Wn~. I3;YH!gv6*(% GH 3 x2{NN p]pU Y0V3AfY^Vf QONx| )a|P[ra) qD 0pp@pp e11 k*UF0l Qt{ ,$%Jili@4$k ])N-N#$6W }MZ?2?Z% bC RT! K ?Lv 6` &1=Bnr=3 Y[V5 YvLzzLzL4e D7jV2VZ5NgUV MbTK8 dzQB^d 86]+J(J(:L~e].

ghUh CD #$oO#? P2(o}5( pMV{ U{+ 7Gosjs9[6|oOG| !~T`TT4y U \[,0 ;axhq ~ qf\B9 hA !Y_ BsCfd Ha ${EUT%}0_^9] J%c!V.

OHK { Fu* F-8h rAUi)PAUY8ZA ;/\,?-|Wh|/; Bf2+2_XW1 q~DS:SDS _N Ub$QLX$A lM-4 SNm[ym[mA- ?*lC/,/ vt\ [9[b[vkwGoG. 7dq LnkQ--n8:n: )#%[P e 9&!E fr ec: 35ep /DF #]E m&I;ZS&IeU[7 Y?/D7, # /U&U=CUHPC ha$`Uh qVkO6YS.

!TAxO2_

Ue$ &s

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão